CR20240371A - Vacunas terapéuticas anti-alfa-sinucleína - Google Patents

Vacunas terapéuticas anti-alfa-sinucleína

Info

Publication number
CR20240371A
CR20240371A CR20240371A CR20240371A CR20240371A CR 20240371 A CR20240371 A CR 20240371A CR 20240371 A CR20240371 A CR 20240371A CR 20240371 A CR20240371 A CR 20240371A CR 20240371 A CR20240371 A CR 20240371A
Authority
CR
Costa Rica
Prior art keywords
sub
present
defined above
peptide antigen
synuclein
Prior art date
Application number
CR20240371A
Other languages
English (en)
Spanish (es)
Inventor
Maxime Ayer
Andrea Pfeifer
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of CR20240371A publication Critical patent/CR20240371A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CR20240371A 2022-02-09 2023-02-09 Vacunas terapéuticas anti-alfa-sinucleína CR20240371A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22156006 2022-02-09
EP22156007 2022-02-09
PCT/EP2023/053259 WO2023152260A1 (en) 2022-02-09 2023-02-09 Anti-alpha-synuclein therapeutic vaccines

Publications (1)

Publication Number Publication Date
CR20240371A true CR20240371A (es) 2024-10-16

Family

ID=85175955

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240371A CR20240371A (es) 2022-02-09 2023-02-09 Vacunas terapéuticas anti-alfa-sinucleína

Country Status (11)

Country Link
US (1) US20250152684A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475878A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506472A (cg-RX-API-DMAC7.html)
KR (1) KR20240147981A (cg-RX-API-DMAC7.html)
AU (1) AU2023219059A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248093A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002370A1 (cg-RX-API-DMAC7.html)
CR (1) CR20240371A (cg-RX-API-DMAC7.html)
IL (1) IL314865A (cg-RX-API-DMAC7.html)
MX (1) MX2024009485A (cg-RX-API-DMAC7.html)
WO (1) WO2023152260A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250135293A (ko) * 2023-01-26 2025-09-12 에이씨 이뮨 에스에이 리포좀 구조체
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
EP2659907A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
WO2013173827A2 (en) * 2012-05-18 2013-11-21 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
CA3003943A1 (en) 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient
TW202333768A (zh) * 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
MA52180A (fr) * 2018-04-10 2021-02-17 Ac Immune Sa Vaccins thérapeutiques anti-abêta
JP7898188B2 (ja) * 2020-08-04 2026-07-31 エイシー イミューン ソシエテ アノニム 免疫原性化合物

Also Published As

Publication number Publication date
US20250152684A1 (en) 2025-05-15
IL314865A (en) 2024-10-01
EP4475878A1 (en) 2024-12-18
CA3248093A1 (en) 2023-08-17
WO2023152260A1 (en) 2023-08-17
KR20240147981A (ko) 2024-10-10
JP2025506472A (ja) 2025-03-11
AU2023219059A1 (en) 2024-07-25
MX2024009485A (es) 2024-08-14
CL2024002370A1 (es) 2024-12-27

Similar Documents

Publication Publication Date Title
CL2024002370A1 (es) Vacunas terapeuticas anti-alfa-sinucleína.
KR960031602A (ko) 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조 방법
CA2489227A1 (en) Hla-a24-restricted cancer antigen peptides
BR9306820A (pt) Conjugado de um antígeno fracamente imunogênico e um veículo peptideo sintetico vacina processos para melhorar a imunogenicidade de uma molecula de antigeno fracamente imunogenico e para imunizar um hospedeiro mamífero
EP1619202A3 (en) immunotherapeutic methods using epitopes of wt-1 and gata-1
NZ551802A (en) A hyperimmune serum-reactive antigen consisting of a polypeptide comprising an amino acid sequence in SEQ ID NO:422 and antigenic fragments thereof
MXPA04000597A (es) Peptidos novedosos de la proteina g del virus sincicial respiratorio (rsv), y su uso en una vacuna.
CA2242878A1 (en) Induction of immune response against desired determinants
MX2023001483A (es) Compuestos inmunogenicos.
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
MX2021014497A (es) Peptidos.
WO2003084568A3 (de) Verwendung eines lipopeptids oder lipoproteins als adjuvans bei therapeutischer oder prophylaktischer vakzinierung
WO2021239980A9 (en) A peptide cocktail
DK193589D0 (da) Hidtil ukendt polypeptid og fremgangsmaade til dets fremstilling
MXPA06014393A (es) Peptidos oligomericos y su uso para el tratamiento de infecciones por vih.
RU2010126154A (ru) Эпитопные пептиды stat3
WO2001027136A3 (fr) Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
NZ592340A (en) A method for making a virus vaccine compising Replikin peptides
CA3058567A1 (en) Novel peptide based pcsk9 vaccine
PE20010237A1 (es) GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS OmpH, PEPTIDOS Y PROTEINAS RELACIONADOS Y SUS USOS
MX2025008523A (es) Construccion liposomal
AU2003303218A1 (en) Peptides and their use for the treatment of hiv infections
WO2024052542A3 (en) A peptide cocktail
CA2446390A1 (en) Antigenic epitopes of factor viii, inhibitors directed against said epitopes and use thereof
Brass et al. Semisynthesis of peptides-New strategy for specific protection and deprotection of the α-amino group of recombinantly-produced peptide fragments